dc.contributor.author | Scherbaum, Norbert | |
dc.contributor.author | Seiffert, Friedrich | |
dc.contributor.author | Schifano, Fabrizio | |
dc.contributor.author | Specka, Michael | |
dc.contributor.author | Bonnet, Udo | |
dc.contributor.author | Bender, Stefan | |
dc.date.accessioned | 2020-10-27T10:30:19Z | |
dc.date.available | 2020-10-27T10:30:19Z | |
dc.date.issued | 2020-10-19 | |
dc.identifier.citation | Scherbaum , N , Seiffert , F , Schifano , F , Specka , M , Bonnet , U & Bender , S 2020 , ' High lifetime, but low current, prevalence of new psychotropic substances (NPS) use in German drug detoxification treatment young inpatients ' , Progress in Neuro-Psychopharmacology and Biological Psychiatry . https://doi.org/10.1016/j.pnpbp.2020.110144 | |
dc.identifier.issn | 0278-5846 | |
dc.identifier.uri | http://hdl.handle.net/2299/23339 | |
dc.description.abstract | Background: Over the last 15 years, a large number of new psychoactive substances (NPS) has been identified, with their use being associated with a range of acute medical and psychopathological complications. Conversely, NPS addictive liability levels have not been systematically assessed in clinical populations. Aims of the study: Investigating the lifetime and current prevalence of NPS use in a sample of substance use disorder (SUD) patients admitted to an inpatient detoxification treatment centre. Methods: Assessment of previous/current NPS intake carried out with the means of standardised questionnaire based on the European version of Addiction Severity Index. Results: Some 206 patients (males 77.1%; average age: 30.7 years-old; most typical diagnosis: opioid/polydrug dependence) participated to the survey. Roughly half (e.g. 111/206; 53.9%) of them reported a lifetime use of NPS, most typically synthetic cannabinoids. Conversely, the current prevalence of NPS use was 2.9%; no NPS dependence condition was diagnosed. Among NPS users, 56.3% reported severe side-effects such as heavy anxiety or psychotic experience, and 64% reported an aversion of ever using the respective NPS again, whilst 84.3% of those reporting a single NPS intake reported an aversion. Discussion: The sharp contrast between lifetime prevalence of NPS use and prevalence of current use might be explained by the high frequency of severe side effects reported by NPS users. | en |
dc.format.extent | 360549 | |
dc.language.iso | eng | |
dc.relation.ispartof | Progress in Neuro-Psychopharmacology and Biological Psychiatry | |
dc.subject | New psychoactive substances | |
dc.subject | NPS | |
dc.subject | detoxification | |
dc.subject | side effects | |
dc.subject | clinical sample | |
dc.subject | addictive disorders | |
dc.title | High lifetime, but low current, prevalence of new psychotropic substances (NPS) use in German drug detoxification treatment young inpatients | en |
dc.contributor.institution | Department of Clinical and Pharmaceutical Sciences | |
dc.contributor.institution | Centre for Health Services and Clinical Research | |
dc.contributor.institution | Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit | |
dc.contributor.institution | School of Life and Medical Sciences | |
dc.contributor.institution | Department of Clinical, Pharmaceutical and Biological Science | |
dc.description.status | Peer reviewed | |
dc.date.embargoedUntil | 2021-10-19 | |
rioxxterms.versionofrecord | 10.1016/j.pnpbp.2020.110144 | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |